1HOOTON C, DEMPSEY C, KEOHANE J, et al. Helicobacter pylori: prevalence of antimicrobial resistance in clinical isolates [J]. Br J of Biomed Sci, 2006, 63(3): 113-115.
2ROMANO M, IOVENE MR, RUSSO MI, et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates[J]. J Clin Pathol, 2008, 61(10): 1112-1115.
3RAYMOND J, LAMARQUE D, KALACH N, et al. High level of antimicrobial resistance in french Helieobacter pylori isolates[J]. Helicobacter, 2010, 15(1): 21-27.
4HIYAMA T, TANAKA S, MASUDA H, et al. Prevalence of He- licobacter pylori resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan [J]. J Gastroenterol Hepatol, 2003, 18(10): 1202-1207.
5BOYANOVA L, MITOV I. Geographic map and evolution of pri- mary Helicobacter pylori resistance to antibacterial agents[J]. Ex- pert Rev Anti Infec Ther, 2010, 8(1): 59-70.
6QURESHI NN, MORIKIS D, SCHILLER NL. Contribution of specific amino acid changes in penicillin binding protein-1 to amoxicillin resistance in clinical Helicobacter pylori [J]. Antimi- crob Agents Chemother, 2010, 8(1): 59-70.
7GLUPCZYNSKI Y, BROUTET N, CANTAGREL A, et al. Com- parison of the E Test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori[J]. Eur J Clin Microbiol Infect Dis, 2002, 21: 549-552.
8MEGRAUD F, LEHN N, LIND T, et al. Antimicrobial suscep- tibility testing of Helicobacter pylori in a large multicenter trial: the MACH2 study [J]. Antimicrobial Agents and Chemotherapy, 1999, 43: 274722752.
9BOYANOVA L, ILIEVA J, GERGOVA G, et al. Evaluation of clinical and socio-demographic risk factors for antibacterial re- sistance of Helicobacter pylori in Bulgaria [J]. J Med Microbiol, 2009, 58(1): 94-100.
10OSATO MS, REDDY R, REDDY SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clar- ithromycin in the United States[J]. Arch Intern Med, 2001, 161 (9): 1217-1220.
